Naresh Tanna was named Chief Financial Officer of Precision Biosciences Inc. As of November 6, 2026, Precision Biosciences Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 27, 2026, naming 3 appointments (Form 8-K, July 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Precision Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Alex Kelly · Role: Chief Operating Officer · 8-K, 2026-07-27
- · In / out: In · Person: Naresh Tanna · Role: Chief Financial Officer · 8-K, 2026-07-27
- · In / out: In · Person: Mei Burris · Role: Chief Accounting Officer · 8-K, 2026-07-27
Precision Biosciences Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-27. It names 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Precision Biosciences Inc files it.
Also on the record for Precision Biosciences Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G/A, by Octagon Capital Advisors LP | 5.73% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.01% of the class | 5%+ stakes | Source |
| August 24, 2026 | Stake report, Schedule 13G/A, by Weinstein Benjamin | 4% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by Empery Asset Management, LP | 4.99% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by Lynx1 Capital Management LP | 5.4% of the class | 5%+ stakes | Source |
| April 15, 2026 | Stake report, Schedule 13G/A, by Empery Asset Management, LP | 7.63% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 4.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Bleichroeder LP | 8.21% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G, by Octagon Capital Advisors LP | 9.99% of the class | 5%+ stakes | Source |
| January 27, 2026 | Stake report, Schedule 13G, by Aberdeen Group plc | 8.88% of the class | 5%+ stakes | Source |
| January 22, 2026 | Stake report, Schedule 13G, by Empery Asset Management, LP | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Precision Biosciences Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Precision Biosciences Inc and the records around it.
Precision Biosciences Inc elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Readout Capital, LP also filed stake reports on 1 other company: TScan Therapeutics, Inc. (Sep 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Watch Precision Biosciences Inc
Get an email when Precision Biosciences Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Precision Biosciences Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Precision Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Precision Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-27 | In | Chief Operating Officer | 8-K, 2026-07-27 | ||
| 2026-07-27 | In | Chief Financial Officer | 8-K, 2026-07-27 | ||
| 2026-07-27 | In | Chief Accounting Officer | 8-K, 2026-07-27 |
Who leads Precision Biosciences Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Mei Burris, appointed (filed 2026-07-27).
- Chief Financial Officer: Naresh Tanna, appointed (filed 2026-07-27).
- Chief Operating Officer: Alex Kelly, appointed (filed 2026-07-27).
New leaders reset buying decisions — get the Full Report on Precision Biosciences Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Precision Biosciences Inc, with the record behind each one.
Find candidates like Chief Operating Officer at Precision Biosciences IncEvery change, in the filing's words
Appointed: Alex Kelly, Chief Operating Officer
As part of these leadership changes, the Board appointed Alex Kelly, age 60, as Chief Operating Officer of the Company.
Appointed: Naresh Tanna, Chief Financial Officer
Appointment of Chief Financial Officer In connection with Mr. Kelly's promotion to Chief Operating Officer, the Board appointed Naresh Tanna, age 45, as Chief Financial Officer of the Company.
Appointed: Mei Burris, Chief Accounting Officer
On the Effective Date, Mei Burris, age 40, the Company's Vice President of Finance, will be designated as and assume the responsibilities of principal accounting officer and Chief Accounting Officer.
- On July 23, 2026, the Board of Directors (the "Board") of Precision BioSciences, Inc. (the "Company") approved the appointment of a new Chief Operating Officer, the appointment of a new Chief Financial Officer, and other changes to its executive leadership team.
- Each of these changes is effective as of August 1, 2026 (the "Effective Date").
- Mr. Kelly previously has served as the Company's Chief Financial Officer since May 2021.
- Mr. Kelly and the Company mutually agreed to Mr. Kelly's promotion from the role of Chief Financial Officer to Chief Operating Officer, and this transition was not the result of any disagreement with the Company or its Board relating to the Company's operations, policies or practices or any issues regarding its accounting policies or practices.
- In connection with Mr. Kelly's appointment as Chief Operating Officer of the Company, the Compensation Committee of the Board approved an increase to Mr. Kelly's annual base salary to $510,000 with a target annual bonus equal to 45% of his annual base salary, effective as of the Effective Date.
- No other changes were made to Mr. Kelly's existing employment agreement or compensation in connection with his appointment as Chief Operating Officer.
- As Chief Financial Officer, Mr. Tanna will serve as the Company's principal financial officer.
Tools for this story
Each opens in a new tab, filled in for Precision Biosciences Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.